Aclaris Therapeutics (ACRS) FCF Margin: 2017-2025
Historic FCF Margin for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to -332.07%.
- Aclaris Therapeutics' FCF Margin fell 83828.00% to -332.07% in Q3 2025 from the same period last year, while for Sep 2025 it was -273.20%, marking a year-over-year decrease of 20503.00%. This contributed to the annual value of -107.88% for FY2024, which is 14695.00% up from last year.
- Aclaris Therapeutics' FCF Margin amounted to -332.07% in Q3 2025, which was up 41.07% from -563.53% recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' FCF Margin registered a high of 506.21% during Q3 2024, and its lowest value of -1,454.44% during Q1 2022.
- In the last 3 years, Aclaris Therapeutics' FCF Margin had a median value of -444.97% in 2024 and averaged -472.15%.
- In the last 5 years, Aclaris Therapeutics' FCF Margin soared by 90,300bps in 2022 and then slumped by 83,828bps in 2025.
- Aclaris Therapeutics' FCF Margin (Quarterly) stood at -1,150.90% in 2021, then surged by 90,300bps to -247.90% in 2022, then spiked by 20,691bps to -40.99% in 2023, then tumbled by 5,605bps to -97.04% in 2024, then tumbled by 83,828bps to -332.07% in 2025.
- Its FCF Margin stands at -332.07% for Q3 2025, versus -563.53% for Q2 2025 and -900.34% for Q1 2025.